Article

Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives

Published 23 Nov 2023

Read Full Article

Article

Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial

Published 07 Nov 2023

Read Full Article

Article

Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial

Published 07 Nov 2023

Read Full Article

Article

Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum

Published 01 Nov 2023

Read Full Article

Article

Recce Pharma welcomes approval for faster RECCE327 infusion rate

Published 25 Oct 2023

Read Full Article

Article

Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval

Published 24 Oct 2023

Read Full Article

Article

Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development

Published 23 Oct 2023

Read Full Article

Article

Recce Pharma says commercial potential of its anti-infectives is gaining recognition

Published 11 Oct 2023

Read Full Article

Article

Recce Pharmaceuticals raise to progress advanced anti-infective

Published 09 Oct 2023

Read Full Article

Article

Global fund takes stake in Recce as synthetic antibiotic developer raises $11m

Published 06 Oct 2023

Read Full Article

Article

Recce Pharmaceuticals raises further funds to progress trials from entitlement shortfall

Published 06 Oct 2023

Read Full Article

Article

Recce Pharmaceuticals advances anti-infective development and clinical trials in FY23

Published 02 Oct 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial

Published 22 Sep 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) paves its way to commercialisation with breakthrough antibiotic, R327

Published 20 Sep 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial

Published 28 Aug 2023

Read Full Article

Article

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Published 24 Aug 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial

Published 22 Aug 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds

Published 21 Aug 2023

Read Full Article

Article

Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections

Published 08 Aug 2023

Read Full Article

Article

Recce Pharmaceuticals awarded Australian patent for lead anti-infectives

Published 04 Aug 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule

Published 24 Jul 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial

Published 19 Jul 2023

Read Full Article

Article

Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

Published 19 Jul 2023

Read Full Article

Article

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance

Published 12 Jul 2023

Read Full Article

Article

Recce Pharmaceuticals — Gearing up for more R327 studies

Published 11 Jul 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial

Published 10 Jul 2023

Read Full Article

Article

Recce Pharmaceuticals lands ethics approval for expanded UTI studies

Published 30 Jun 2023

Read Full Article

Article

Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial

Published 29 Jun 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327

Published 29 Jun 2023

Read Full Article

Article

Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial

Published 29 May 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott

Published 29 May 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023

Published 08 May 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives

Published 11 Apr 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) selects CMAX for phase I/II UTI clinical trial

Published 20 Feb 2023

Read Full Article

Article

Recce Pharmaceuticals boosts finances with A$6.21 million in R&D rebate payments

Published 25 Jan 2023

Read Full Article

Article

For this pharma boss, fishing is an experience in positivity

Published 16 Jan 2023

Read Full Article

Article

Recce Pharmaceuticals (ASX:RCE) granted notification of intent for Australian patent

Published 10 Jan 2023

Read Full Article

Article

ASX:RCE

Published 12 Apr 2023

Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors...

Read Full Article

Article

Recce Pharmaceuticals locks

Published 12 Apr 2023

In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the...

Read Full Article

Article

Director Trades

Published 12 Apr 2023

A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close...

Read Full Article

Article

Health & Biotech

Published 12 Apr 2023

The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.

Read Full Article

Article

Health & Biotech

Published 12 Apr 2023

Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having...

Read Full Article

Article

Sky Business News

Published 12 Apr 2023

Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..

Read Full Article

Article

S&P Global

Published 12 Apr 2023

Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...

Read Full Article

Article

The West Australian

Published 12 Apr 2023

WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...

Read Full Article

Article

The Australian

Published 12 Apr 2023

Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...

Read Full Article

Article

BioWorld

Published 12 Apr 2023

Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...

Read Full Article

Article

Fighting Antibiotic Resistance

Published 12 Apr 2023

The world needs new classes of antibiotics Antibiotics The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...

Read Full Article

Article

Nature Biopharma

Published 12 Apr 2023

New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...

Read Full Article

Article

Coronavirus crisis

Published 12 Apr 2023

Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights...

Read Full Article

Article

The Australian - Research Special Report 2020

Published 12 Apr 2023

A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…

Read Full Article

Article

Pharmafiles 2020: Synthetic Anti-Infectives

Published 12 Apr 2023

AMR is a ticking time bomb argues Recce CEO James Graham...

Read Full Article

Article

H.C. Wainwright Global Life Sciences Conference

Published 12 Apr 2023

Click here for full Press Release and Presentation

Read Full Article

Article

AusBiotech Journal 2020 Vol 30

Published 12 Apr 2023

A NEW CLASS OF ANTIBIOTICS

Read Full Article

Article

AusBiotech Journal 2020 Vol 30

Published 12 Apr 2023

ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs

Read Full Article

Article

PharmaShots Interview w Recce CEO James Graham

Published 12 Apr 2023

James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.

Read Full Article

Article

AusBiotech Journal 2021 Vol 31

Published 12 Apr 2023

A REVOLUTIONARY APPROACH against antimicrobial resistance

Read Full Article

Article

Recce tapping European investor interest

Published 12 Apr 2023

Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Read Full Article

Article

Recce tapping European investor interest

Published 12 Apr 2023

Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Read Full Article

Article

Proactive Investors - The smart money in medicine: the silent pandemic

Published 12 Apr 2023

Recce Pharmaceuticals is working on a solution.

Read Full Article